Management of cancer genomic board and preparation of genomic report

Kohei Nakamura, Hiroshi Nishihara

研究成果: Article査読

抄録

The accumulation of gene alteration is the major pathogenicity of any types of cancer. The concept of precision cancer medicine is therefore the individualized treatment based on the driver gene alteration in each case. The cancer gene profiling (CGP) test, so called gene panel test, will be the major clinical examination to identify the driver gene alteration usually using the FFPE tissue from the surgically resected pathological archives, and government insurance system will cover the examination fee for limited number of cancer patients since 2019 in Japan. Although genetic profiling of tumors is a potentially powerful tool to predict drug sensitivity and resistance, its routine use has been limited because physicians are often unfamiliar with interpretation and incorporation of the information into practice. We established a molecular tumor board (MTB) and clinical tumor board (CTB) system to interpret individual patients' tumor genetic profiles and provide treatment recommendations upon the molecular report.

本文言語English
ページ(範囲)1141-1148
ページ数8
ジャーナルJapanese Journal of Cancer and Chemotherapy
47
8
出版ステータスPublished - 2020 8月

ASJC Scopus subject areas

  • 医学一般

フィンガープリント

「Management of cancer genomic board and preparation of genomic report」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル